Children’s Hospital of Fudan University, Sydney Children’s Hospital and the University of Sydney have jointly patented new antibody-drug conjugates comprising an antibody targeting GD2 ganglioside covalently linked to cytotoxic drugs potentially useful for the treatment of osteosarcoma.

Beijing Double-Crane Runchuang Technology Co. Ltd. has discovered new Toll-like receptor 7 (TLR7) and/or TLR8 antagonists potentially useful for the treatment of rheumatoid arthritis, systemic lupus erythematosus, cutaneous lupus erythematosus, dermatomyositis, hidradenitis suppurativa, polymyositis, psoriasis and Sjogren’s syndrome, among others.

Inventisbio Co. Ltd. and Inventisbio LLC have disclosed new proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase-binding moiety coupled to a signal transducer and activator of transcription 6 (STAT6)-targeting moiety potentially useful for the treatment of cancer.

Shanghai Aryl Pharmtech Co. Ltd. and Zhejiang Hisun Pharmaceutical Co. Ltd. have identified new CTP synthase 1 (CTPS1) inhibitors potentially useful for the treatment of lymphoma and solid tumors.

Genfleet Therapeutics (Shanghai) Co. Ltd. has divulged new phosphatidylinositol 3-kinase (PI3K) inhibitors potentially useful for the treatment of cancer, Alzheimer’s disease, aging, diabetes, Parkinson’s disease, asthma, cardiovascular disease and allergy, among others.

Brightgene Bio-Medical Technology Co. Ltd. has patented new calcitonin receptor (CALCR; CT-R) and amylin AMY3 receptor agonists potentially useful for the treatment of obesity and metabolic disorders.

Duke Street Bio Ltd. has identified new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors potentially useful for the treatment of cancer.

The University of Edinburgh has disclosed new benzoxazol mammalian target of rapamycin (mTOR; FRAP1) inhibitors potentially useful for the treatment of cancer, autoimmune, metabolic diseases, fibrosis, parasitic infections, genetic, inflammatory and neurological disorders.

Merck Sharp & Dohme LLC (MSD) has synthesized new benzimidazole derivatives acting as NLRP3 inflammasome inhibitors. As such, they are potentially useful for the treatment of atherosclerosis, metabolic dysfunction-associated steatohepatitis (MASH), neuroinflammation, inflammatory skin, inflammatory joint and autoimmune disease, Alzheimer’s and Parkinson’s disease, among others.